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DementiaThe effects of estrogens are pleiotropic, affecting multiple bodily systems. Changes from the body’s nat-
ural fluctuating levels of estrogens, through surgical removal of the ovaries, natural menopause, or the
administration of exogenous estrogens to menopausal women have been independently linked to an
altered immune profile, and changes to cognitive processes. Here, we propose that inflammation may
mediate the relationship between low levels of estrogens and cognitive decline. In order to determine
what is known about this connection, we review the literature on the cognitive effects of decreased estro-
gens due to oophorectomy or natural menopause, decreased estrogens’ role on inflammation – both
peripherally and in the brain – and the relationship between inflammation and cognition. While this
review demonstrates that much is unknown about the intersection between estrogens, cognition, inflam-
mation, we propose that there is an important interaction between these literatures.
Crown Copyright  2016 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hormone manipulations are common in women; these include
variations in hormones administered for cessation of menstrua-
tion, menopausal symptoms, and ovarian removal for disease pro-
phylaxis (Barbaglia et al., 2009; Whiteman et al., 2008). The latter
two cases principally affect either women in natural menopause or
young women who carry the Breast Cancer 1 and 2 gene variant
(BRCA1 and BRCA2). In spite of the fact that the former is due to
the natural process of aging, and the latter, to the removal of the
ovaries, they are similar in that both lead to decreased levels of
17b-estradiol (E2) that ultimately leave women with lower levels
of estrogens. Converging lines of research suggest that low levels
of estrogens may lead to cognitive decline. Low levels of estrogens
have been implicated in the etiology of dementia in women (Rocca
et al., 2014; Yaffe et al., 1998) – for instance, there is a greater pro-
portion of women with Alzheimer’s disease (AD) than men, not
always accounted for by women having a greater longevity
(Andersen et al., 1999; Fratiglioni et al., 1997) – and an increased
risk of dementia in women who have undergone surgical removal
of the ovaries at a young age (Rocca et al., 2007). An outstanding
question is whether the relationship between low levels of estro-
gens, cognitive decline and dementia is due to the direct effect ofthe lack of E2 on neurons or indirect effects on other body systems
and, in particular, the immune system.
For the most part, the mechanism for this cognitive decline has
been attributed to the effects of low levels on neurons directly.
Animal studies in female rodents have shown that low levels of
E2 have direct effects on neurons leading to synapse loss and lower
connectivity (e.g. Woolley and McEwen, 1994; Woolley, 2007),
which are important hallmarks of AD in humans (Terry et al.,
1991). Young female rats that have had their ovaries removed
(ovariectomized; OVX’d) have significantly lower levels of the
synaptic proteins phosphosynapsin and synaptophysin in the hip-
pocampus (O’Leary et al., 2009; Velázquez-Zamora et al., 2012),
while OVX’d females with E2 treatment show increased spine den-
sity of hippocampal CA1 pyramidal cells (Woolley and McEwen,
1994) that form synaptic contacts, producing increased neuronal
excitability (Woolley et al., 1997).
However, another possible mechanism for cognitive decline
might be brain inflammation due to the response of the immune
system to decreased levels of E2 (Straub, 2007). Women who have
had their ovaries removed as well as those in natural menopausal
exhibit systematic inflammation (e.g. Cioffi et al., 2002; Abu-Taha
et al., 2009). Increased levels of pro-inflammatory markers such
as interleukin-1 (IL-1), and tumor necrosis factor-a (TNF-a) have
been found in women who have had their ovaries surgically
removed (e.g. Pacifici et al., 1991). Levels of pro-inflammatory
markers interleukin-6 (IL-6), IL-1, TNF-a increase significantly in
menopausal women when E2 synthesis declines (Pfeilschifter
et al., 2002). Inflammation is also implicated in the pathophysiol-
ogy of AD in both men and women (e.g. Altsteil and Sperber,
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between cognitive decline, low levels of estrogens, and
inflammation.
Support for the idea that peripheral inflammation might affect
cognition comes from research looking at inflammation and cogni-
tion directly. Male mice given an intravenous injection of human
interleukin-1a (IL-1a) take significantly more trials to learn the
response that would allow them to avoid a shock, but this memory
impairment reverses when an antibody against IL-1a is injected
first (Banks et al., 2001). Lastly, that inflammatory molecules can
breach the blood–brain barrier (BBB) and are linked to cognitive
impairment (Banks et al., 2002) provide the premise that inflam-
mation may mediate the relationship between low levels of estro-
gens and cognitive changes. This idea is elaborated upon in a
review exploring the evidence that AD is an inflammatory neu-
rodegenerative disease as a result of disruption of the BBB
(Sohrabji, 2007). This review provides one of the only cohesive dis-
cussions of estrogens in relation to inflammation in the pathogen-
esis of AD, a condition of cognitive decline.
The BBB functions as a physical barrier made up of astrocytes,
endothelial cells and pericytes that barricade circulating immune
cells from the central nervous system (Abbott et al., 2006). Tight
junctions between adjacent microvascular endothelial cells are
regulated by the transmembrane proteins, claudin, occludin, and
junction adhesion molecules, which are important for maintaining
the integrity of the BBB (Mandell and Parkos, 2005). Thus, the BBB
is normally closed to most immune cells that cannot easily traverse
these barriers. However, decreased E2 has been shown to increase
the permeability of the BBB in female rats (Bake and Sohrabji,
2004) and in female mice (Burek et al., 2010). Specifically, follow-
ing treatment with 2 lg/kg E2 per day, endothelial cells extracted
from the brains of female mice show an upregulated expression of
the tight junction protein, claudin-5, and an increased
transendothelial electric resistance, suggesting that E2 is impor-
tant in maintaining the BBB’s integrity (Burek et al., 2010). As well,
in response to high hydrostatic pressure, the BBB of OVX’d female
rats show a 500% increase in permeability as compared to that of
rats with intact ovaries. With the administration of 0.5 mg E2
and 5 mg estriol, differences between the estrogens-treated group
and those with intact ovaries disappeared (Cipolla et al., 2009).
Young, untreated OVX’d rats also show significantly greater dye
transfer across the BBB, further indicating that low levels of E2
levels are associated with a compromised BBB integrity (Bake
and Sohrabji, 2004).
Other research in female rodents support these findings. OVX’d
mice treated with lipopolysaccharide (LPS), an endotoxin used to
experimentally induce systemic inflammation, have increased
levels of cytokines in their brains (Brown et al., 2010). Increased
dye transfer into the brain was observed, but E2 treated mice did
not show this increase dye transfer suggesting that breakdown of
the BBB due to low levels of E2 plays a role in the ensuing neuroin-
flammation. Independent of the levels of E2, cytokines can degrade
the BBB on their own; exposure to cytokines like IL-6 and
interleukin-1b (IL-1b) can degrade the BBB (de Vries et al., 1996).
More research will be needed to disentangle whether low levels
of E2 and increased levels of cytokines independently contribute to
a breakdown of the BBB, or whether they act synergistically to
potentiate this effect. That said, experiments as previously
described support the possibility that breakdown of the BBB may
be a mechanism by which low levels of E2 affect cognition via sys-
temic inflammation.
Based on the evidence that there might be convergence
between low levels of estrogens (E2, primarily), decreases in cogni-
tion, and brain inflammation along with a possible mechanism, the
objective of this review is to describe some of works from these lit-
eratures in order to explore the hypothesis that inflammation maymediate the relationship between low levels of E2 and cognitive
decline. The relationship between estrogens and cognition has pre-
viously been reviewed elsewhere (e.g. Henderson and Sherwin,
2007; Vearncombe and Pachana, 2009), as have the literatures on
inflammation and cognition (e.g. Cunningham and Hennessy,
2015; Goshen and Yirmiya, 2007; Trollor and Agars, 2010) and
on estrogens and the immune system (e.g. Fish, 2008; Kovats,
2015; Straub, 2007). Our specific objective is to report on a focused
selection of research in both animal models and humans that inter-
faces the interactions between low levels of estrogens, cognition,
and inflammation.2. Literature search
A literature search was conducted using combinations of the
following key words: (1) menopause, oophorectomy, ovariectomy,
estradiol, estrogen replacement, hormone replacement, (2)
inflamm⁄, neuroinflamm⁄ (wildcards used to respectively to
search for variations of the terms inflammation, neuroinflamma-
tion), cytokine, interleukin, interferon or (3) memory, cognit⁄, ver-
bal, spatial, attention, dementia. Searches were conducted using
the PubMed, Web of Science and PsychINFO databases, allowing
us to survey the biomedical and behavioral literature. Articles pub-
lished between 1980 and May 2015 were selected based the rele-
vance of their titles and abstracts. We excluded articles that were
primarily focused on mental health, obesity, asthma, HIV,
endometriosis, and cancer. We also excluded articles that focused
on health comorbidities unrelated to inflammation or cognitive
changes. Where possible, we selected research conducted on
female animals. However, if a particular area lacked research con-
ducted on females alone, we reported on experiments using mixed
sex populations or males. The interconnections between subjects
and number of hits are illustrated in Fig. 1. Although we have pro-
vided the number of queries returned from each combination of
search terms, they are presented only to illustrate the breadth of
the literature. This strategy left us with 1023 studies in both ani-
mals and humans that we believe are key to exploring what is
known about low levels of estrogens, cognition, and inflammation.3. Cognition and low levels of estrogens
In this section, we describe the research exploring the relation-
ship between low levels of estrogens and cognitive functioning in
humans and in animal models. In humans, neuropsychological
tests are used to assess various cognitive domains that are sub-
served by different areas of the brain. Global cognition is assessed
across a number of domains, and the most common assessment to
measure this in humans is the Mini Mental State Examination
(MMSE; Folstein et al., 1975), especially in participants that may
have cognitive impairment. A common experimental paradigm in
animals includes training them to perform a task followed by
memory testing after a certain amount of time has elapsed
(Kinnavane et al., 2015).
We found 341 relevant studies that discussed low levels of
estrogens and cognitive changes or dementia. Of these, 170
focused on humans and 171 focused on animal models. One hun-
dred and eighty-four articles used oophorectomy or ovariectomy
(a combined figure for humans and animal models) and 155 used
natural menopause in humans.
This literature focuses primarily on E2 and the following
conditions of low levels of E2: (1) women with bilateral
oophorectomy and (2) women in natural menopause. Ovarian
removal, as opposed to natural menopause, is a procedure that
induces an abrupt loss of E2, as the ovaries are a woman’s
primary source of endogenous E2 (Ryan, 1982). Endocrine
Cognitive Changes
Cognition, memory, verbal, spatial, attention, 
dementia, Alzheimer’s
Total: 341 hits
OR: 184
NM: 155
Human: 170
Animal: 171
Low Levels of Estrogens
Oophorectomy, ovariectomy, menopause, estrogen 
therapy, hormone therapy
Inflammation
Inflammation, immune, cytokine, interleukin, 
interferon
Total: 3 hits
OR: 0
NM: 0
Human: 0
Animal: 3
Total: 430 hits
OR: 1
NM: 0
Human: 258
Animal: 172
Total: 249 hits
OR: 128
NM: 120
Human: 107
Animal: 142
Fig. 1. We proposed that the relationship between low levels of estrogens and cognitive changes is mediated by inflammation. The interrelationships between estrogens,
inflammation and cognition have been studied extensively as seen by the number of hits returned per combination of search terms. To date, there has yet to be an
investigation of whether inflammation mediates the relationship between low levels of estrogens and cognitive changes in women. Note that the breakdown of articles into
the categories of ovary removal, natural menopause, human and animals are not mutually exclusive. OR = ovary removal; NM = natural menopause.
Table 1
Serum E2 levels at different phases in women.
Phase E2 range (pg/mL) Average age Onset
Cycling women, menses 30–50a 12e,f–51g n/a
Cycling women, follicular phase 130–400a 12e,f–51g n/a
Cycling women, luteal phase 100–150a 12e,f–51g n/a
Pregnancy, first trimester 118–2947b Reproductive age n/a
Pregnancy, second trimester 1278–7192b Reproductive age n/a
Pregnancy, third trimester 3460–6137b Reproductive age n/a
Natural Menopause 2–46c 51g Gradual
Bilateral oophorectomy 6–35d Recommended < 35 for BRCA mutation carriersh; Variable age for other indications Immediate
a Chabbert Buffet et al. (1998).
b Abbassi-Ghanavati et al. (2009).
c Measured two to three years after menopause, at a mean age of 52.3. Range calculated as ±2 standard deviations from the mean, Longcope et al. (1986).
d Measured two to three years after oophorectomy, at a mean age of 48.6 from Chakravarti et al. (1977).
e Anderson and Must (2005).
f Al-Sahab et al. (2010).
g In North America, from Palacios et al. (2010).
h Finch et al. (2014).
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levels of E2 and testosterone (Chakravarti et al., 1977; Korse
et al., 2009). Natural menopause yields a more gradual and less
extreme loss of E2; in natural menopause E2 levels gradually fall
approximately 75% during the menopause transition (Overlie
et al., 1999). Although average levels of endogenous E2 do not
significantly differ in women who are naturally menopausal and
those who have bilateral oophorectomy (Chakravarti et al.,
1977), there is a greater range of possible E2 levels in naturally
menopausal women as the ovaries continue to secrete small
amounts of E2 following menopause (Judd et al., 1974). Table 1
presents typical ranges of serum E2 in women allowing compar-
ison to be made across different types of reproductive hormone
changes, and demonstrating that there is considerable variability
in what low estrogens mean in a given study.3.1. Cognition and oophorectomy
3.1.1. The effects of low levels of E2 and replacement
In general, the literature on women who undergo oophorec-
tomy prior to natural menopause suggests there is a post-
operative cognitive decline, notably in verbal memory (Sherwin,
1988; Phillips and Sherwin, 1992). In a small randomized con-
trolled trial (RCT), women with bilateral salpingo-oophorectomy
(BSO; surgical removal of the ovaries and fallopian tubes) at a
mean age of 45 when tested four months post-surgically per-
formed significantly better on measures of memory, perceptual
speed, and abstract reasoning with injections of E2 valerate (three
injections of 10 mg each over three months) compared to the pla-
cebo phase (Sherwin, 1988). Women with hysterectomy (surgical
removal of the uterus) have no significant cognitive changes
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memory decline; compared to their pre-surgical performance,
women tested at a mean age of 48, three months post-BSO per-
formed significantly worse on the Associate Learning task measur-
ing verbal memory if they received a placebo (Phillips and Sherwin,
1992). In contrast, women who received monthly injections of E2
valerate (10 mg) showed no decline from their pre- to post-
operative performance. Thus, in the placebo group, memory
decline was related to low levels of E2.
Changes in global cognition, or cognitive ability across multiple
domains, has also been found in women post-oophorectomy.
Women with BSO (mean age = 41) show a significant decrease in
performance on the MMSE and subtests of the Wechsler Memory
Scale compared to their own pre-surgical baseline (Farrag et al.,
2002). In this study, the MMSE was administered prior to BSO,
and then again at three and six-months post-surgically. Scores on
the MMSE and all subtests of the Wechsler Memory Scale were sig-
nificantly lower at six months post-BSO compared to baseline. Per-
formance was related to E2 levels; women with more than a 50%
decrease in serum E2 experienced greater memory decline, sug-
gesting changes were linked to low levels of E2. Further, based
on a composite of 17 tests, surgical menopause, whether induced
by hysterectomy or oophorectomy, are associated with a steeper
decline on global cognition in elderly women (mean age = 78)
(Bove et al., 2014). Results suggest that in addition to memory, cog-
nition in general, may be compromised by oophorectomy.
Recent epidemiological studies show that oophorectomy prior
to natural menopause is associated with a higher risk for dementia
(Phung et al., 2010; Rocca et al., 2007) and parkinsonism in later
life (Rocca et al., 2008). The incidence of dementia is higher in
women who undergo the surgery at a younger age (Rocca et al.,
2007). Furthermore, the study reported that the risk of dementia
is higher in women who had a bilateral oophorectomy compared
to a unilateral oophorectomy (removal of one ovary), and use of
estrogen replacement up to age 50 in women with oophorectomy
eliminates the increased risk of dementia. On the other hand,
oophorectomy in women after menopause does not alter the risk
of AD (Imtiaz et al., 2014).
Thus, results from RCTs, observational, and epidemiological
studies provide evidence that loss of the ovaries that produce E2
before natural menopause induces changes in memory, and that
the higher incidence of dementia in women with oophorectomies
may be related to the severity and number of years since E2 with-
drawal. Taken together, decline on measures of verbal and global
cognition suggest that young women with oophorectomy and
hence, low levels of estrogens, with no E2 replacement may be at
risk for further cognitive decline since verbal, episodic memory
tasks are highly sensitive predictors of progression to AD (Bastin
and Salmon, 2014; Tierney et al., 2005). Epidemiological studies
showing higher incidence of dementia in women with oophorec-
tomy prior to natural menopause support the decline toward
dementia.
Similar to the cognitive changes observed in humans following
oophorectomy, ovariectomy (OVX) in animal models have been
linked to deficits in memory and learning (e.g. Singh et al., 1994).
Female rats OVX’d between three to four months of age and tested
at five or 28 weeks post-OVX performed significantly worse on the
active avoidance task compared to OVX’d rats that received
implants restoring physiological levels of E2 starting three weeks
post-surgically (Singh et al., 1994). Both two and twenty-five
weeks of continuous E2 treatment was associated with signifi-
cantly better performance and accelerated learning. Similarly, rhe-
sus macaques tested at a mean age of 21 (OVX’d at a mean age of 9)
on the delayed nonmatching-to-sample task, a measure of visual
recognition, had significantly fewer correct responses than intact
macaques of a comparable age (mean age = 23) when tested witha 10-min delay period after the recognition phase (Lacreuse
et al., 2000). These studies not only demonstrate the importance
of higher levels of E2 for performance on certain cognitive tasks
but also a potential homology across mammals of the effects of
ovarian removal with removal at a young age, detrimental to
cognition.
3.1.2. Animal models
Animal models are instrumental in elucidating possible mecha-
nisms underlying changes in cognition following oophorectomy.
One of these mechanisms might be decreased connectivity in
regions mediating cognition. A lower synaptic density in the CA1
region of the hippocampus (Silva et al., 2003), and a lower den-
dritic spine density in the CA1 and CA3 hippocampal pyramidal
cells as well as in pyramidal cells of the prefrontal cortex
(Wallace et al., 2006) are found in OVX’d, female rats. Similarly, a
significant spine synapse loss in the CA1 region of the hippocam-
pus is found in female mice following OVX or treatment with letro-
zole, an aromatase inhibitor that reduces levels of E2 synthesized
(Zhou et al., 2010). In addition, E2 attenuates neuronal death by
inhibiting the expression of the anti-apoptotic gene Bax and
decreasing expression of the pro-apoptotic gene Bcl-2 (Sales
et al., 2010). Linking these findings with the human condition of
dementia, synapse loss is recognized as the basis for cognitive
impairment in patients with AD (Terry et al., 1991), and detectable
at autopsy in the CA1 region of older adults with mild AD (Scheff
et al., 2007). Thus, by facilitating communication between neurons
by increasing spine density and supporting the viability of neurons
by preventing apoptosis, E2 may be important to staving off cogni-
tive decline.
3.2. Cognition and natural menopause
Natural menopause is often used to model a state of E2 with-
drawal despite the fact that the ovaries continue to make and
secrete androgens that can be aromatized to E2 (Longcope et al.,
1980). In addition to the continued synthesis of estrogens, natural
menopause is also confounded by cultural expectations and per-
ceptions of aging (Hogervorst et al., 2000). Perhaps because of both
the biological and the socio-cultural aspects of natural menopause
as well as large variations in circulating E2 levels in menopausal
women (Toniolo et al., 1994), the literature using this model is rife
with small effect sizes and inconsistent findings (Hogervorst et al.,
2000; McCarrey and Resnick, 2015).
Studies examining cognition in menopause have been con-
ducted cross-sectionally comparing different groups of women,
or longitudinally to determine changes over the menopause transi-
tion. One cross-sectional study reports no cognitive differences
between women whether they are categorized as pre-
menopausal (mean age = 48), early peri-menopausal, late peri-
menopausal, or post-menopausal (mean age = 52) after adjusting
for sociodemographic variables and menopause-related symptoms
(Luetters et al., 2007). However, other cross-sectional studies
report that untreated menopausal women show frontal dysfunc-
tion (Keenan et al., 2001), or a performance decrement on mea-
sures of verbal learning, memory, motor ability, and working
memory in the first year after the final menstrual period (Weber
et al., 2013). Some longitudinal studies also show small decreases
in verbal fluency (Fuh et al., 2006) and processing speed on the
Symbol Digit Modalities Test (Greendale et al., 2010) through the
menopause transition. While one literature review reports no sig-
nificant relationship between levels of endogenous E2 and episodic
memory or executive functioning in menopausal women
(Henderson and Popat, 2011), another meta-analysis reports lower
scores on measures of delayed verbal memory and phonemic flu-
ency as well as higher depressive symptoms in menopausal
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cognitive impairment (Burt et al., 1995), the increased risk for
depressive disorders in menopause may be a source of variability
across studies.
Results from various RCTs looking at the effects of estradiol-
based hormone therapy (HT) in menopausal women show varying
effects (Lethaby et al., 2008). Results from the Women’s Health Ini-
tiative Study of Cognitive Aging (WHISCA) suggest that HT is detri-
mental to menopausal women. This large-scale drug trial found a
significant increase in the risk of dementia and mild cognitive
impairment (Shumaker et al., 2003), as well as lower scores on
measures of verbal memory and learning in women treated with
0.625 mg/day equine estrogen (EE) and 2.5 mg/day medroxypro-
gesterone acetate (Resnick et al., 2006). Thus, results disagree with
the oophorectomy literature, and in reconciling these findings, the
hypothesis of a critical period for beneficial effects of HT is now a
major consideration (Maki, 2013). Since a major weakness of the
WHISCA was the age of participants – women were age 65 or older
upon study enrolment – there is concern that the detrimental
effects on cognition are due to the age of administration. There is
evidence that estradiol-based HT is beneficial for maintenance of
cognitive functioning if administered in the perimenopause, but
yields at best, null, or at worst, detrimental effects if administered
later than the early stages of menopause (Maki, 2013). Thus, the
administration of HT in the WHISCA may have been outside the
critical window of positive estrogenic effects, underscoring that
when studying the effects of HT on cognition, it is important to
take into account the type of HT as well as the method, age, and
mode of administration (Miranda et al., 1999).
3.2.1. Animal models
In non-human primates such as the rhesus macaque or the
baboon that, as a species, have a cessation of the reproductive cycle
like menopause, females typically do not live long enough to
undergo menopause (Bellino and Wise, 2003), making it difficult
to study them during this life stage. However, when menopausal
rhesus macaques have been tested as late as 20–27 years old, they
perform significantly worse on a delayed response task compared
to age-matched, premenopausal macaques (Roberts et al., 1997).
Further, perimenopausal and menopausal rhesus macaques (mean
age = 29) perform more poorly on the delayed nonmatching-to-
sample task compared to an age-matched, premenopausal group,
demonstrating a deficit in delayed recall (Hara et al., 2012).
Although research on cognitive changes in non-human primates
is limited, both studies suggest that the reduction in ovarian hor-
mone secretion with menopause is associated with a performance
decrement on memory recall that is assessed following a longer
delay period.
While the non-human primate model has a scarcity of studies,
rodents are often used in studies of hormone depletion with aging.
However, evidence from rodent models of menopause is more dif-
ficult to interpret because neither rats nor mice undergo a human-
like menopause. Instead, rodents undergo reproductive senescence
characterized by the cessation of reproductive cycles due to the
secretion of either constant high or low levels of ovarian hormones
(Nelson et al., 1981). The first stage of reproductive senescence is
persistent estrus, where E2 is elevated, followed by persistent dies-
trus, where E2 is diminished (Kermath and Gore, 2012). This pat-
tern is substantially different from the endocrine changes
observed in women in whom, after their last menstrual period,
E2 typically decreases over one year (Longcope et al., 1986).
Nevertheless, studies of reproductive senescence in rats and
mice can be instructive. One experimental manipulation to female
rodents that simulates the endocrine conditions of human meno-
pause is the administration of 4-vinyl cyclohexane diepoxide
(VCD), which accelerates ovarian follicle atresia in order to depletethe primordial and primary follicles (Springer et al., 1996). After
treatment of VCD in mice, levels of follicle-stimulating hormone
(FSH) and luteinizing hormone (LH) increase with a concomitant
decrease of E2, mimicking the pattern of endocrine changes in
menopausal women (Mayer et al., 2004). VCD models are valuable
as they allow comparisons to be made in rodent models between a
transitional and a surgical menopause. For example when middle-
aged, female rats were treated with VCD or OVX’d and then tested
on the water radial arm maze task, it was found that rats treated
with VCD before OVX perform better than rats with OVX alone
(Acosta et al., 2009). These results support the idea that a gradual
and incomplete decrease in the levels of estrogens has less of an
effect on cognitive outcomes than the abrupt E2 cessation that
comes with oophorectomy or OVX. Thus, the data from natural
menopause in both humans and animals is far less certain as to
the effects of low levels of estrogens on cognition.4. Inflammation and low levels of estrogens
The following section will discuss how estrogens affect levels of
cytokines involved in cell signaling, changes in macrophage activ-
ity and cell adhesion molecules that facilitate the extravasation of
leukocytes through the endothelium, all of which contribute to
inflammation. We found 249 studies on low levels of estrogen
and inflammation, of which 107 focused on humans and 142 on
animal models. There were 128 studies that looked at inflamma-
tion and oophorectomy, and 120 studies that looked at inflamma-
tion and natural menopause.
Studies discussed here describe mainly the detrimental effects
of inflammation, but it should be acknowledged that inflammation
can sometime be beneficial. Neuroinflammation can attenuate
damage in the brain by promoting controlled cell death and neu-
ronal growth after injury (Ekdahl et al., 2009). Some proteins are
associated with an anti-inflammatory response such as the cytoki-
nes interleukin-10 (IL-10), which can inhibit NF-KB mediated
upregulation of other cytokines (Clarke et al., 1998), or the IL-
1RA (interleukin-1 receptor antagonist) that inhibits the family of
IL-1 cytokines (Dinarello, 1994). However, chronicity of an inflam-
matory state may be cytotoxic (e.g. Willard et al., 2000), and
increased levels of markers such as TNF-a and IL-1b have been
implicated in the pathogenesis of dementia (Blasko et al., 2004).4.1. Inflammation and oophorectomy
4.1.1. Peripheral immune system
The literature suggests that, in general, reduction of endoge-
nous E2 following oophorectomy is associated with increased
peripheral inflammatory markers (e.g. Kalyan et al., 2011; Kumru
et al., 2004) just as oophorectomy is associated with cognitive
decline in young women. Levels of C-reactive protein (CRP; an
acute phase inflammatory protein) measured from serum are three
times higher in women after BSO with hysterectomy than in age-
matched women with intact ovaries (Kalyan et al., 2011). There
are other changes in inflammatory markers in women with BSO
plus hysterectomy (mean age = 49) when compared to these mark-
ers pre-surgically including significant increases in CD8+ cytotoxic
T-cells, a significant decrease of CD19+ B-cells, a decrease in the
CD4+ (T-helper) to CD8+ ratio, and decrease of the cytokines
interleukin-4 (IL-4), and interferon-gamma (IFN-c) (Kumru et al.,
2004). Following four weeks of treatment with 50 lg transdermal
E2 patches applied once per week, changes in the levels of CD19+,
the CD4+ to CD8+ ratio, and IFN-c reverse, suggesting that these
changes are due to low levels of E2.
While surgeries themselves have been documented to cause
elevation of CRP, IL-6 and other inflammatory markers due to
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women with hysterectomy only as a control group for surgical
trauma (e.g. Pacifici et al., 1991; Cantatore et al., 1995). In women
who undergo BSO and hysterectomy prior to natural menopause,
there are higher levels of IL-1, TNF-a, and granulocyte–macro-
phage colony-stimulating factor (GM-CSF) post-surgically whereas
there were no changes in the hysterectomy-only controls (Pacifici
et al., 1991). The increase of these inflammatory markers occurs
concomitantly with a significant decrease of endogenous E2 mea-
sured at a week post-BSO. Following a daily regime of 0.625 mg/-
day oral conjugated equine estrogen, levels of IL-1, TNF-a, and
GM-CSF all return to pre-surgical levels within four weeks of treat-
ment. Hysterectomy only is not associated with any changes in
cytokine levels, indicating that the increased cytokine levels are
due to the changes in levels of E2 post-BSO and not to a urogenital
surgery per se (Pacifici et al., 1991). Levels of IL-1 and IL-6 are sig-
nificantly elevated at six months post-BSO compared to pre-
surgical levels, supporting the idea that inflammatory changes
after BSO are due to low levels of E2 and that they are sustained
unless E2 is replaced (Cantatore et al., 1995).
Animal models for low levels of E2 and inflammation corrobo-
rate human studies, by showing that OVX is associated with
changes in the peripheral immune response with increases in
inflammatory markers such as: TNF-a, IL-1b, macrophage inflam-
matory protein-1, and macrophage colony-stimulating factor (e.g.
Benedusi et al., 2012; Cenci et al., 2000). One possible mechanism
for this may be induction of the transcription factor NF-KB via
binding of estrogens on the two estrogen receptors ERa and ERb
(Kalaitzidis and Gilmore, 2005), which in turn regulates the
expression of cytokines, cell adhesion molecules, chemokines and
others inflammatory genes (O’Neill and Kaltschmidt, 1997). Treat-
ing OVX’d mice with 17a-ethinylestradiol (EE) leads to suppres-
sion of NF-KB-induced genes and subsequently decreases levels
of vascular cell adhesion molecule (VCAM-1), TNF-a and the che-
mokine RANTES (Evans et al., 2001). Treatment with the estrogen
receptor antagonist ICI 182, 780 also inhibits the reduction of
VCAM-1, TNF-a and RANTES by EE treatment, suggesting that EE
binding to the ERs leads to anti-inflammatory effects, although
the receptor subtype is not specified in the study (Evans et al.,
2001). Taken together, the effects of OVX on increased inflamma-
tory markers and the reduction of markers mediated by the estro-
gen receptors underscores the relationship between inflammation
and low levels of estrogens.
Another component of the peripheral immune system on which
estrogens may act are T-cells (Straub, 2007). Increased T-cell pro-
liferation has been observed in the bone marrow of mice OVX’d
at four weeks, and in turn, there is an increase in TNF-a (Cenci
et al., 2000). Likewise, mice OVX’d at four weeks have significantly
decreased levels of IFN-c, an inhibitor of T helper 17 (Th17) cells
(Maret et al., 2003). Low levels of E2 leading to increased levels
of TNF may stimulate Th17 T-cells, causing a downstream effect
of increased interleukin-17 (IL-17), which plays a primary role in
chronic inflammation (Straub, 2007).
4.1.2. Central nervous system
The central nervous system is also affected by peripheral
immune system response. T-cells are implicated in the etiology
of multiple sclerosis (MS), an autoimmune disease of the central
and peripheral nervous system which affects approximately two
to three times more women than men worldwide (Disanto and
Ramagopalan, 2013). A hallmark of MS is demyelination of the
axons and inflammation of the CNS, resulting in motor changes,
fatigue, pain, vision loss, and cognitive symptoms (Lublin and
Reingold, 1996).
Animal models of multiple sclerosis such as experimental
autoimmune encephalomyelitis (EAE), causes inflammatorydamage to the myelin sheaths of neurons via the action of Th1
and Th17 helper T-cells (Constantinescu et al., 2011). Low levels
of estrogens also affect this disease model. Eight to twelve week-
old OVX’d mice treated with EAE have an earlier disease onset
compared to control females, and EAE mice – OVX’d or intact –
treated with 3.2 lg of E2 benzoate show significant delays in the
onset of symptoms (Jansson et al., 1994). OVX’d EAE mice also
show a significantly earlier onset and disease severity than sham
operated females, suggesting that estrogens modulate the presen-
tation of EAE pathology (Offner et al., 2000). Furthermore, E2 treat-
ment is associated with a dose-dependent inhibition of EAE in
which higher doses produce lower scores on the cumulative dis-
ease index, a method for quantifying the pathological signs of
EAE. Thus, levels of estrogens affect a nervous system disease that
is influenced by inflammation.
Brain inflammatory mechanisms are upregulated after OVX too,
as brain macrophages (microglia) are affected by low levels of E2
(Vegeto et al., 2001). After treatment with LPS, OVX’d, six-week
old rats show microglial activation that was significantly reduced
after administration of 50 lg/kg E2 (Vegeto et al., 2003). Activated
microglia, or the primed microglia phenotype, is associated with
the ability to synthesize pro- or anti-inflammatory cytokines
depending on the microenvironment of the central nervous system
(Perry and Holmes, 2014). One way that low levels of E2 may
increase neuroinflammation is therefore through activation of
microglia.4.2. Inflammation and natural menopause
4.2.1. Peripheral immune system
Natural menopause brings peripheral immune system changes
(Gameiro et al., 2010). Menopausal women (mean age = 56) show
increased leukocyte adhesion and expression of interleukin-8 (IL-
8), monocyte chemotactic protein-1 (MCP-1), RANTES and macro-
phage inflammatory protein-1a (MIP-1a), suggesting a low-grade,
systematic inflammation (Abu-Taha et al., 2009). Menopausal
women compared to pre-menopausal controls show elevated
levels of cytokines, including IL-6, IL-18, IL-2, IL-4, GM-CSF, and
granulocyte-colony stimulating factor (G-CSF) (Cioffi et al., 2002;
Yasui et al., 2007), suggesting that the lower levels of E2 following
menopause are associated with a pro-inflammatory phenotype.
HT seems to reverse the increase of pro-inflammatory markers
in menopausal women (Störk et al., 2002). Menopausal women
(mean age = 60) treated for 48 weeks with 1 mg/day E2 in combi-
nation with a low dose progestin have reduced levels of intercellu-
lar adhesion molecule 1 (ICAM-1), VCAM-1, and E-selectin, all
involved in leukocyte extravasation or movement through the
endothelium (Störk et al., 2002). An even lower dose of HT
(0.25 mg/day E2) given for 12 weeks in menopausal women (mean
age = 75) is associated with significantly reduced levels of CRP
compared to the placebo (Prestwood et al., 2004).4.2.2. Central nervous system
Menopausal women also show immune changes localized to
the brain (Sárvári et al., 2012). Tissue from the National Institute
on Aging Alzheimer’s Disease brain banks show that
macrophage-associated gene expression is upregulated in samples
from the postcentral and superior frontal gyrus in menopausal
women compared to younger, pre-menopausal women (Sárvári
et al., 2012). Since menopausal women are older, one might con-
clude that such changes in gene expression were related to age
(Franceschi et al., 2000). However, genes related to inflammation
and the immune system are proportionally more highly expressed
in older women than in older men (Berchtold et al., 2008). Taken
together, results suggest that upregulation of inflammatory genes
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withdrawal in menopause.
Also suggestive of the effects of low levels of estrogens on cen-
tral nervous system inflammation is the observation that the
severity of MS symptoms varies across a woman’s lifespan
(Smith and Studd, 1992). There is a modulation of MS by hormone
fluctuation most notably linked with remission of symptoms dur-
ing the third trimester of pregnancy – when estriol and estradiol
levels are elevated – and followed by a relapse postpartum when
E2 levels are at their lowest (Korn-Lubetzki et al., 1984; Nott
et al., 1976). Fifty-four percent of women with MS report worsen-
ing of symptoms following menopause, but 75% of women using
HT report significantly better functioning compared to those not
taking HT (Smith and Studd, 1992). These findings demonstrate
that the severity of MS is linked to levels of circulating estrogens
in women as symptoms are intensified when E2 is low. Taken
together, observations of both peripheral and central nervous sys-
tem inflammation at different reproductive stages of a women’s
life suggest that the immune system, especially inflammatory
markers and inflammatory conditions are affected by levels of
estrogens.5. Inflammation and cognitive changes
We found 430 studies that discussed inflammation and cogni-
tive changes or dementia, of which 258 focused on humans and
172 focused on animals. Although there is research on older
humans (both males and females), the proportion of menopausal
participants is seldom reported, and menopause status could only
be inferred on the basis of age.5.1. Human studies
There is a vast literature on inflammation and dementia that
typically considers both sexes together. Nevertheless, it is worth
considering as it points to the role of inflammation in cognitive
decline. The observation that individuals (without regard to sex
of participants) with rheumatoid arthritis who have used anti-
inflammatory medications also had a lower incidence of AD gener-
ated a subsequent body of literature on inflammation and AD
(McGeer et al., 1990, 1996). For the population at large, self-
reported non-steroidal anti-inflammatory drugs (NSAID) use of
two years or more is associated with a significant decrease in the
relative risk of AD (Stewart et al., 1997). This finding has been
replicated in the Rotterdam study, which also reports that usage
of NSAIDs for over two year according to prescription records
reduces the relative risk of AD approximately fivefold (in’t Veld
et al., 2001). Thus it appears that decreasing inflammation by use
of NSAIDs confer protection against AD (Szekely et al., 2004) with
one caveat: several clinical trials of cyclooxygenase-2 (COX-2)
inhibitors – a form of NSAID – in older adults with AD have had
limited success suggesting that decreasing inflammation after neu-
rodegeneration has started does not curtail ongoing neurodegener-
ation and cognitive decline (McGeer and McGeer, 2007).
Inflammation may have a role in the etiology of mild cognitive
impairment (MCI), a transitional stage between normal cognitive
changes with aging and probable AD (Petersen et al., 1997), in
older women (Trollor et al., 2011). Older women between ages
70 and 90 (presumed to be menopausal by age) with MCI, but
not men, have significantly elevated levels of TNF-a (Trollor
et al., 2011), suggesting a potential sex difference in the relation-
ship between inflammation and cognitive impairment.
That said, in older, healthy women without MCI, the evidence
that NSAID use affects cognitive functioning is mixed. A study of
NSAID use in women between ages 70 and 81 shows that use ofeight or more years confers better global cognition scores and
lower odds of cognitive decline compared to never-users (Kang
and Grodstein, 2003). However, an RCT assessing the effect of a
low dose of aspirin in women aged 65 and older failed to find
any significant differences between the treated and placebo group,
except for a slightly decreased risk of decline on categorical fluency
performance in the group taking aspirin (Kang et al., 2007). It
should be noted, however, that aspirin is a relatively weak NSAID
and the strongest findings have been using ibuprofen (Anthony
et al., 2000). Ovarian status was not discussed in these studies,
hence there is no information as to whether any of the participants
have had an oophorectomy. To date, there have been no other clin-
ical trials on the effects of other NSAIDs on cognitive functioning in
healthy women.
Most of the studies examining cognitive performance in associ-
ation with inflammatory markers have been conducted using both
sexes. In a community-based sample of older women and men,
levels of IL-6 and CRP are negatively associated with global cogni-
tion and executive function (Jefferson et al., 2011; Schram et al.,
2007). Higher levels of IL-6 in plasma are associated with lower
scores on the Telephone Interview for Cognitive Status-modified
(Economos et al., 2013). Older adults (mean age = 71) with meta-
bolic syndrome who have higher than mean levels of IL-6 and
CRP have significantly lower scores on the modified Mini Mental
State Examination, suggesting an association between inflamma-
tion and global cognitive decline (Yaffe et al., 2004). Despite some
inconsistencies in the literature, CRP and IL-6 have been most fre-
quently reported to be associated with lower cognitive perfor-
mance in healthy, older adults (Trollor and Agars, 2010). Thus
the data suggest that decreasing inflammation protects against
AD, and high levels of CRP and IL-6 is correlated with lower scores
on tests of global cognition.
5.2. Animal models
Animal models using LPS treatment have provided more
insights into inflammation and cognitive impairment. Male mice
treated with seven injections of 250 lg/kg LPS over one week exhi-
bit memory and learning deficits, attributed to neuronal apoptosis
in the hippocampus and cortex (Lee et al., 2008). LPS-induced neu-
roinflammation is also linked to an elevation of beta amyloid levels
in male mice, which is associated with neuronal apoptosis (Lee
et al., 2008). Further, a single intracerebroventricular injection of
5 lL LPS to male rats leads to ultrastructural damage to the hip-
pocampal CA1 pyramidal neurons, including irregular chromatin
masses, thickening of the perinuclear space, swelling of the mito-
chondria and rupture of the mitochondrial membranes (Gong
et al., 2010). LPS male rats treated with 40 mg/kg ibuprofen or
5 mg/kg hydrogen sulfide, an anti-inflammatory compound that
inhibits NF-KB, do not show impairment on the Morris water maze
and treatment further attenuates damage to the CA1 pyramidal
neurons (Gong et al., 2010). The relationship between LPS-
induced inflammation and cognitive changes has been replicated
by other groups on fear conditioning and water maze performance
(Pugh et al., 1998; Zarifkar et al., 2010). Further, administration of a
2 lL injection of LPS to the hippocampus and anterior cortex of 4.5-
month old mice transgenic for a tau mutation (both sexes) induces
a significant increase of CD45, a microglial marker, as well as an
increase of tau phosphorylated at the Ser396 position in the hip-
pocampal CA1 which reduces its ability for binding to micro-
tubules (Lee et al., 2010; Bramblett et al., 1993), demonstrating
that inflammation may facilitate tau phosphorylation and the for-
mation of neurofibrillary tangles observed in AD.
When female animal models are used to study the relationship
of inflammation and cognition, inflammation is again associated
with memory deficits. Year-old female mice given five days of
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Morris water maze task than rats given saline injections
(Sparkman et al., 2005). Furthermore, the effects of LPS are exacer-
bated by age; two-month old mice do not show the same degree of
impairment as year-old mice. A single 1 mg/kg LPS exposure to
female rats is associated with a 240% increase of activated micro-
glia in the dentate gyrus and 35% reduction of hippocampal neuro-
genesis, showing that inflammation in the CNS can suppress
processes that support learning and memory (Monje et al., 2003).
The hippocampus and particularly the CA1 pyramidal neurons is
one of the earliest brain regions to acquire neurofibrillary tangles
and neuropil threads (Braak and Braak, 1991). Thus, there is a role
for inflammation in the formation of neurofibrillary tangles, a hall-
mark neuropathology of AD.
Inflammation also has a detrimental effect on long term poten-
tiation (LTP) in the hippocampus, the long-lasting, enhanced
synaptic transmission induced by the high-frequency stimulation
of coincident afferent nerve fibers, usually measured in the CA1
pyramidal neurons and thought to underlie the formation of mem-
ories (Kerchner and Nicoll, 2008; Shors and Matzel, 1997). LTP is a
form of synaptic plasticity, playing a central role in the mainte-
nance of cognitive function (Kerchner and Nicoll, 2008; Matynia
et al., 2002). Injection of LPS in male rats induces attenuation of
LTP in the dentate gyrus of the hippocampus (Hauss-Wegrzyniak
et al., 2002) and entorhinal cortex (Vereker et al., 2000) resulting
in a significant decrease of the excitatory post-synaptic potential
in two key regions for the consolidation of memory. Injection of
LPS also leads to an increase in reactive oxygen species production,
which results in increased caspase-1 activity, an IL-1 converting
enzyme (Vereker et al., 2000). IL-1b increase then leads to
increased c-Jun N-terminal protein kinases (JNK) phosphorylation
and decreased glutamate release and therefore impairment in
learning and memory. Taken together, these studies support an
association between LPS-induced inflammation and AD pathology
as well as impairment of the underlying mechanism for memory
formation leading to cognitive decline on hippocampal-
dependent tasks. However, they do not shed much light on the
effects of ovarian hormones on inflammation and cognition.6. Estrogens, inflammation, and cognitive changes
In this section, we discuss what is known about the intersection
of estrogens, inflammation, and cognition. With the exception of
the previously discussed review exploring the evidence that AD
is an inflammatory neurodegenerative disease and, in women, is
due to low levels of estrogens modulating BBB permeability allow-
ing peripheral immune response to enter the brain (Sohrabji,
2007), there is no further empirical support for the idea that
inflammation may mediate the relationship between low levels
of estrogens and cognition in women. There are only three studies
of inflammation and estrogens that consider their combined effects
on cognitive changes in OVX’d rats.
One of the very few studies to consider the relationship
between inflammation and cognition in the context of low levels
of estrogen is a study on Huntington’s disease induced by 3-
Nitropropionic acid (3-NPA), a mitochrondrial toxin that produces
lesions and memory impairments (Menze et al., 2015). While
inflammation was not studied directly, levels of inflammatory
mediators changed in the brain with the administration of either
E2 or a phytoestrogen, genistein. 3-NPA, OVX’d rats treated with
E2 (2.5 mg/kg) or genistein (5, 10 and 20 mg/kg), perform signifi-
cantly better than rats with no hormone treatment. In addition,
the expression of COX-2, an inflammatory mediator, was signifi-
cantly lower in the hippocampus of rats treated with E2, while
20 mg/kg of genistein reduced expression of COX-2 in both thehippocampus and cortex. Since treatment with E2 and genistein
lowered both COX-2 expression and improved memory, results
suggest that the improvement may be attributable to the anti-
inflammatory effect of E2 or phytoestrogens.
In LPS (250 lg/kg) rats, passive avoidance performance is detri-
mentally affected by OVX at 12 weeks (Pourganji et al., 2014). In
the training phase, rats in an apparatus with both light and dark
compartments separated by a door are given a shock in the dark
compartment. After a period of time in their cages, rats were
returned to the apparatus for the test phase at one, and 24 h later.
LPS-OVX’d rats spend significantly more time in the dark compart-
ment compared to OVX-only or LPS-only mice in spite of condi-
tioning to the shock stimulus. These results suggest that memory
impairment caused by LPS is exacerbated in the OVX’d rats that
have low levels of endogenous E2.
In addition to the absolute levels of E2, how and when E2 treat-
ment is administered can have differential effects. In a study using
rats also OVX’d at 12 weeks and treated with LPS, continuous
administration of E2 (maintaining blood levels of 30 pg/mL) for
two months is paradoxically associated with significant impair-
ment on the water maze task compared to LPS-OVX’d rats given
the placebo (Marriott et al., 2002). These results are conflicting
with those previously reporting that even 25 weeks of continuous
E2-treatment starting three weeks after OVX in rats is associated
with improvements on the passive avoidance task (Singh et al.,
1994). Despite the counterintuitive results in light of the research
previously presented in support of E2 treatment in OVX’d animals
being beneficial, this study points to the fact that timing and
dosage of E2 require careful calibration. At the same time, results
also suggest that research into anti-inflammatory treatments for
early cognitive changes may be fruitful. Clearly, more studies are
needed not only in humans, but in animal models using OVX and
LPS that evaluate cognition.7. Discussion
Given the number of women who undergo oophorectomy
(Whiteman et al., 2008), and that women represent two thirds of
current AD patients (Hebert et al., 2013), it is increasingly impor-
tant to understand the mechanisms mediating cognitive decline
in women. Older women have lower levels of estrogens and these
are linked with both cognitive changes and inflammation. Thus,
inflammation may be an important mediator to these cognitive
changes.
We have reviewed the literature on estrogens and cognition,
estrogens and inflammation, inflammation and cognition, and on
the combination of all three in order to determine what is known
about inflammation as a mediator of cognitive changes in women.
We included as a proxy for low levels of estrogens, oophorectomy,
OVX, and natural menopause. We have found that while there are
studies in humans and animal models supporting the effects of
estrogens on cognition and on inflammation individually, there is
little directly linking inflammation with cognitive changes and
almost none on the interaction between low levels of estrogens,
inflammation, and cognitive changes.7.1. Summary of the literature
Our search revealed numerous studies demonstrating that
chronic, low E2 levels following oophorectomy are associated with
cognitive impairments in both humans and animal models (e.g.
Sherwin, 1988; Wallace et al., 2006). There are also many studies
that have found elevated inflammatory markers in women with
oophorectomies (Kumru et al., 2004). Further supporting the
hypothesis that inflammation is associated with low levels of
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naturally menopausal women (Störk et al., 2002), suggesting that
low levels of E2 elicit an inflammatory response that can be
reversed by HT. We also found papers linking inflammation to cog-
nition by showing that inflammation can inhibit neurogenesis
(Ekdahl et al., 2003), affect differentiation of hippocampal precur-
sor cells (Monje et al., 2003), and decrease LTP in the hippocampus
(Yirmiya and Goshen, 2011). Despite the fact that all the pieces are
present to suggest that low levels of E2 leading to inflammation
which in turn, affects cognition, we found scant literature putting
all of these pieces together with only one review making the direct
link between low levels of estrogens, inflammation and dementia
in women (Sohrabji, 2007).
Thus, one may question why, in spite of these links, more
research has not emerged on the secondary effects of E2 with-
drawal. One possibility is that the animal literature contains pow-
erful examples of estrogens’ direct effects on neurons (e.g. Woolley
and McEwen, 1994; Woolley, 2007). Another possibility is that
estrogens have often been described in the literature as ‘‘neuropro-
tective” (e.g. Wise et al., 2011), which taken out of context, may
lend to the discourse that estrogens alone, act directly on neuronal
health and therefore cognitive functioning. As a result, less atten-
tion is paid to pathways by which E2 withdrawal might affect cog-
nition other than by its direct effects on neurons.
One example of such a pathway might be through the vasomo-
tor symptoms experienced during menopause, which manifest in
the form of hot flashes and night sweats (McKinlay and Jefferys,
1974). As the pathophysiology is currently understood, E2 reduc-
tion with natural or surgical menopause leads to upregulation of
the serotonin receptor 5-HT2A in the hypothalamus, which upon
activation, is associated with a hyperthermic response
(Berendsen, 2002). In naturally menopausal women who are not
using hormone therapy, the frequency of hot flashes measured
with a skin conductance monitor is associated with lower verbal
memory and verbal fluency performance (Maki et al., 2008), sup-
porting that vasomotor symptoms are correlated with declines in
specific cognitive domains. While hormone therapy is commonly
prescribed as an add-back for the decline in E2, the principal actor
in this case is not E2, but rather secondary mechanisms in the CNS
(Archer et al., 2011). Thus, in a similar way that lower levels of E2
can indirectly affect cognition through hot flashes, lower levels of
E2 may affect cognition through inflammation.
7.2. Menopause and hormone therapy as a model for replacement of
endogenous estrogens
There is a wealth of literature on E2 and cognition at the age of
natural menopause. This may reflect a pragmatic consideration
based on the sheer number of women being treated with HT. It is
estimated that 2.7% of women between ages 45 and 64 in the
USA were using an estrogen-progestin in 2010 (Jewett et al., 2014).
While studying menopause and HT can be helpful in under-
standing the broad effects of ovarian aging and HT as an ameliorat-
ing factor, using menopause and HT as models of low levels of
estrogens and replenishing of hormones to determine cognitive
decline or inflammation are problematic. First, menopause is not
simply the gradual reduction of ovarian function but it also
includes other effects of aging on the entire body. These other
changes might also affect cognition or inflammation but not be
directly related to ovarian involution and low levels of estrogens.
We see an example of that in the observational studies on NSAIDs
not matching the clinical trials of NSAIDs.
As well, despite the abundance of studies that use HT as an
experimental manipulation in examining estrogens and cognition
as well as estrogens and inflammation, there is considerable
heterogeneity around the parameters associated with HT-use andits administration. HT is commonly formulated as estrogens only,
or in combination with progesterone (Furness et al., 2012). For
women who have undergone a hysterectomy, estrogens-only HT
are commonly administered (Hickey et al., 2012), which can either
be naturally derived (e.g. from pregnant mare urine), or synthetic
(Scharbo-Dehaan, 1996). For women with an intact uterus, estro-
gen and progesterone combinations are given because the addition
of progesterone, or its synthetic analogues, protects against uterine
cancer (Hickey et al., 2012). Progesterone is administered either
orally, using an intrauterine device, or transdermally, while estro-
gen is administered orally, intravaginally, or transdermally (Hickey
et al., 2012). Thus, formulations, dosage, age, timing, and modes of
administration differ across studies, rendering it difficult to com-
pare results from experiment to experiment.
7.3. Studies using AD as a proxy for cognitive change when studying
inflammation and cognition
Our review shows a broad literature linking inflammation with
cognition. However, human studies in women alone or that include
an analysis disaggregated by sex are limited. A major focus has
been on inflammation and AD, and this literature has included
men and women, often without disaggregating the data by sex
for analysis. A bibliometric analysis of articles published in 2009
that were sampled from four high-impact journals of each subject
area reveal that for human studies in immunology, <10% of data
were analyzed by sex, and this figure was estimated to be 20%
for studies in neuroscience (Beery and Zucker, 2011). Thus, it is
challenging to interpret results for women due to the underrepre-
sentation of female participants in research as well as how data are
analyzed and reported.
Since a number of clinical trials with COX-2 inhibitors in AD
have not resulted in significant improvement of symptomology
or prognosis (McGeer and McGeer, 2007), it may be prudent to
direct greater efforts to understanding the relationship between
inflammation and cognition in the preclinical stages of AD. In addi-
tion, more research on the relationship between inflammatory
markers and cognition in women would be helpful. Lastly, medical
histories such as oophorectomy, HT, breast cancer treatment have
an effect on both the immune and the nervous systems and thus,
need to be taken into account. This will have important ramifica-
tions since exploring how downstream effects of estrogen with-
drawal could affect cognitive functioning, such as by increasing
inflammation, might lead to the development of therapeutics other
than HT and for both women and men.
7.4. Hormones other than estrogens and inflammation
The synthesis of other reproductive hormones, such as proges-
terone, is affected by menopause and removal of the ovaries
(Overlie et al., 1999). There is some evidence that low levels of pro-
gesterone are implicated in inflammation and that progesterone
replacement can attenuate inflammation in rats. After traumatic
brain injury (TBI), treatment with progesterone (two 16 mg/kg
injections) reduces levels of inflammatory markers in male rat
brains (Pettus et al., 2005). In preclinical models, progesterone also
has a positive effect on spatial learning and memory test perfor-
mance after TBI in male rats (Si et al., 2013). In male rats with
AD-like symptoms, administration of progesterone (4, 8 or
16 mg/kg) improves cognition and decrease levels of TNF-a and
IL-1b (Liu et al., 2013). Research in a female-only mice model of
EAE shows that a progesterone implant decreases secretion of
inflammatory markers IL-2 and IL-17 compared to placebo treat-
ment (Yates et al., 2010). Another study in female mice reveal
decreases in TNF-a, microglial marker CD11b and increased myeli-
nation with progesterone implants compared to controls (Garay
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direct effects on neurons, low levels of progesterone might also
affect inflammation and thereby, cognition.
While evidence in preclinical models of progesterone treatment
for inflammation have been promising, research in humans is more
inconclusive. Some clinical trials of progesterone treatment in
patients of both sexes with TBI (1 mg/kg twice daily for five days)
show reduced mortality (Xiao et al., 2008) and in patients of both
sexes with ischemia there is improvement in functional outcomes
with a low dose (<1 mg/kg) treatment (Wright et al., 2007). Never-
theless, a recent clinical trial failed to demonstrate any benefit of
progesterone treatment (0.05 mg/kg per mL of infusate) for acute
TBI in a population of both sexes, and even a trend suggesting a
detrimental effect in women (Wright et al., 2014). Given the cur-
rent state of mixed findings in humans, more research will be
needed to assess the efficacy of progesterone treatment for
inflammation.
Testosterone is also secreted by the ovaries and is an important
hormone for both women and men. Thus, it is not surprising that
there is a parallel literature in studying the effects of low levels
of testosterone on inflammation as a potential mediator of neu-
rodegeneration in men. Low levels of free testosterone are found
in men with dementia (Bowen et al., 2000; Hogervorst et al.,
2001; Rosario, 2004). Men with AD also have higher levels of LH,
and a positive association between LH and TNF-a (Butchart et al.,
2012). Reproductive hormones, in general, may therefore be impli-
cated in the etiology of cognitive changes acting through inflam-
matory mechanisms.
7.5. Clinical implications
In 2006, 3.3 women per 1000 in the USA had undergone an
oophorectomy (Oliphant et al., 2010). Women undergo the surgery
for various indications, and carrying a deleterious BRCA1 or BRCA2
mutation is amongst one of them. A prophylactic oophorectomy
confers optimal cancer protection before age 35 in female carriers
of a BRCA1/2 mutation with a family history of breast and ovarian
cancer (Finch et al., 2014). For this population electing oophorec-
tomy could induce cessation of ovarian function over fifteen years
prior to the mean age of natural menopause. This means living
longer with low levels of estrogens, and as discussed, these women
are at higher risk of dementia than women who enter natural
menopause. Although short-term HT does not increase the risk of
cancer in BRCA mutation carriers who have not yet had cancer
(Rebbeck et al., 2005), it is contraindicated for women with active
or suspected breast or endometrial cancer (Ross et al., 2000;
Weiderpass et al., 1999). As well, compliance to HT may be limited
(Castelo-Branco et al., 1999; Faulkner et al., 1998), and compliance
may decline over time due to cancer anxieties (Read et al., 2010).
Thus, it is important to understand any and all mechanisms leading
to these cognitive changes in order to develop novel therapies.
Determining whether inflammation mediates the relationship
between low levels of E2 and cognition would open opportunities
for alternate, immunotherapies for attenuating cognitive changes
in women with oophorectomies.
7.6. Future directions
It is important to conduct research that directly links low levels
of estrogens, inflammation and cognition together. To test whether
inflammation is one of the mediators of cognitive decline, we pro-
pose that a study should first demonstrate that low levels of E2 fol-
lowing BSO that is performed prior to natural menopause are
associated with inflammation, and that inflammation is associated
with cognitive changes. Then, inflammation should be inhibited
and ensuing cognition evaluated. This two-step process wouldallow us to assess whether inflammation mediates the relationship
between cognitive decline and low E2 levels. As previously sug-
gested, support of this hypothesis would open opportunities for
clinical trials of anti-inflammatories or other therapeutics to pre-
vent cognitive decline in women who have had their ovaries
removed prior to natural menopause.
While we have proposed inflammation as one of the potential
mediators of the relationship between low levels of E2 and cogni-
tive changes, the effects of E2 loss on other bodily systems and how
they interact with the immune system cannot be understated. For
instance, IL-6 and TNF-a have been shown to elicit an elevated
response of the hypothalamic–pituitary–adrenal (HPA) axis
(Turnbull and Rivier, 1999). A low dose of LPS to menopausal
women stimulates release of adrenocorticotropic hormone (ACTH),
cortisol and cytokine release, but levels are significantly lower in
the group treated with transdermal E2 (Puder et al., 2001). Since
lower levels of IL-1, IL-6 and TNF-a are found in the blood of E2-
treated women, one possibility is that E2’s suppression of the
cytokines subsequently inhibits activation of the HPA axis and
hence, a chronic stress response. Another downstream effect of
low E2 in women is inflammation-related hypertension
(Sandberg et al., in press). In turn, hypertension is predictive of
decrements in cognitive functioning (van den Berg et al., 2009).
Given the multiplicity of E2’s effects throughout the body and
the number of women who undergo oophorectomy, other effects
secondary to low levels of E2 also merit further investigation.
8. Conclusion
We have reviewed the literature and presented examples of
what is known about the intersection of estrogens, cognitive
changes and inflammation in order to better understand the effects
of oophorectomy prior to natural menopause as well as to provide
a platform for new research directions. We have found that while
there is literature supporting an interaction between low levels
of estrogens, inflammation, and cognitive changes, there is no
research to date that has provided empirical support in women.
We call for these studies to be undertaken in order to spur the
development of treatments both for women following natural
menopause or oophorectomy, allowing for the development for
treatments beyond HT.
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